Brain tumours form a group of neoplasms with distinct histological characteristics and different malignancies [Maher 2001]. Various molecular alterations occurring in brain tumors may have diagnostic and predictive values as they are connected with histologically determined tumour types and malignancy grades [Martinez et al. 2009; Martinez and Esteller 2010; Sciume et al. 2010]. Methylation of DNA cytosine residue at the carbon 5 position (m5C) is a common epigenetic marker in many eukaryotes and is often found in the sequence context of CpG. It is assumed that ca 5% of all cytosine residues, i.e. 1% of the nucleic bases, in mammalian genomes are methylated. Although DNA methylation has been viewed as a stable epigenetic mark, studies in the past decade have revealed that this modification is not as static [Wu and Zhang 2010]. In fact, loss of DNA methylation (DNA hypomethylation), has been observed in the specific context and can occur through active, passive or random modification mechanisms. Although the genome in each cell within the body is identical, cell- and tissue-specific profiles of gene transcription, posttranscriptional modification, modifications and translation are specifically regulated by epigenetic mechanisms that include DNA methylation, histone modification and noncoding RNAs [Robertson 2005]. In the central nervous system epigenetic mechanisms serve as main regulators of homeostasis and plasticity development, which are sensitive to local and global environmental, vascular and systemic factors [Martinez and Esteller 2010].
It is generally accepted that cancer initiation and progression are linked to the disruption of red-ox balance of the cell [Grek and Tew 2010]. Current evidences support an idea that cancer cells are generated by enhanced reactive oxygen species (ROS) generation, their accumulation, and down regulation of antioxidant enzymes [Essick and Sam 2010]. The oxidative damage to the cell caused by ROS plays a critical role in the etiology and progression of different neoplasms in humans [Johnstone and Baylin 2010; Jomova and Valko 2011].
Oxygen radicals cause damage to DNA and chromosomes, induce epigenetic alterations, interact with oncogenes or tumour suppressor genes, and finally change the immunological mechanisms [Robertson 2005; Pelizzola and Ecker 2010].
5-methylcytosine (m5C), along with other DNA constituents and the cell components, are targets for ROS, of which the most reactive species is the hydroxyl radical (•OH). Hydroxyl radical causes a wide range of DNA lesions including base modifications, deletions and strands breakage. Radical oxidation of m5C leads to its modification including demethylation and deamination (Fig. 1). It results in decreasing the global (genomic) m5C content in cellular DNA (hypomethylation). Therefore DNA methylation (m5C status) is a sensitive marker of the neoplasm formation effected by the oxidative damage reactions and very characteristic for cancer cells [Robertson 2005].
Measurements of m5C in DNA can be done either by analysing the pattern of methylated target sequences along individual DNA molecules or as an average methylation level at a single genomic locus across many DNA molecules [Rao and Balachandran 2002].
One should remember that 5% of m5C deaminates to thymine under moderately acidic conditions and 2-5% is converted to thymine during the standard overnight incubation with sodium bisulfite [Wu and Zhang 2010].
One can also measure the global DNA methylation changes [Li et al. 2009; Pelizzola and Ecker 2010]. To investigate whether hypomethylation has a causal role in tumour formation, we have analyzed the level of m5C in DNA of human brain tumour tissues using two-dimensional thin layer chromatography (TLC) analysis of [32P] postlabelled DNA components. We have found a correlation of m5C global content in DNA of tumour tissues with their malignancy. We have shown that as m5C amount decreases, the tumour grade of malignancy increases. The elaborated method has a practical application potential in the clinical diagnostics and also as the DNA quality test.
2. Materials and methods
Patients with brain tumours have been operated at the Department of Neurosurgery and Neurotraumatology of Poznań University of Medical Sciences. Brain tumour samples from 577 patients were collected between 2007 and 2010 and stored at -80oC. Histopatological analysis was done in the Neuropathology Laboratory and tumours classified according to the 2007 WHO rules [Louis et al. 2007]. Informed consent for samples and data analysis was obtained from each patient.
DNA was isolated from tumour tissue according to the method described earlier [Miller et al. 1988] or with a commercial kit (A&A Biotechnology, Poland).
Dried DNA (1 g) was digested with 0.02 U of micrococcal nuclease (MN) and 0.001 U spleen phosphodiesterase II (SPD) to mononucleotides (Np) in 50 mM succinate buffer pH 6 containing 10 mM CaCl2 in 3.5 l total volume for 5 h at 37oC. Mononucleotides (0.17 μg) were labelled with 0.1 Ci [γ-32P] ATP (6000 Ci mmol-1, USB) and T4 polynucleotide kinase (1.5 U ) in 3 l of 10 mM bicine-NaOH pH 9.7 buffer containing 10 mM MgCl2, 10 mM dithiothreitol and 1 mM spermidine for 30 min at 37oC.
To remove inorganic phosphate (PPi) 3 l (10 U ml-1) of apyrase (Sigma) in the same 10 mM bicine-NaOH buffer pH 9.7 was added and incubation was continued for 30 min. Finally the 3’ phosphate was cleaved off with 0.2 g RNase P1 in 500 mM ammonium acetate buffer pH 4.5 [Barciszewska 2007].
Separation of [γ-32P]m5C from other nucleotides was performed with thin layer chromatography (TLC) on cellulose plates (Merck) using isobutyric acid:NH4OH:H2O (66:1:17 vol/vol) in the first dimension and 0.1 M sodium phosphate pH 6.8 – ammonium sulfate – n-propanol (100 ml/ 60 g/ 2 ml) in the second dimension. The chromatogram was analyzed with Phosphoimager using Image Quant Software. The amount of m5C was calculated as of the spot intensities ratio of [m5C/(m5C+C+T)] ×100 and expressed as R coefficient. The analysis was repeated 3 times for each probe and results were evaluated.
3. Results and discussion
Low level of some reactive oxygen species (ROS) as superoxide, hydroxyl radical or hydrogen peroxide can enhance cellular survival and stimulate proliferation. However, when that is a concominant with chronic ROS production, redox homeostasis can become imbalanced and normal cells may undergo transformation [Rao and Balachandran 2002]. In the last years many data have been collected that link cell stress to various diseases including cancer, cardiovascular disease, diabetes and neurodegenerative disorders. Current evidence support the hypothesis that cancer cells are characterized by enhanced ROS generation, increased ROS accumulation and the degradation of antioxidant enzymes. There are many explanations how cellular stress induces a disease. It is known that the cell stress causes genetic and epigenetic changes and results in an altered cellular “memory” that drives diseases pathology [Robertson 2005]. The main risk for cancer is a chronic exposure and increasing DNA damage. There is a wealth of data which supports the idea that cancerous cells have aberrant patterns of epigenetic modifications. The best studied epigenetic modification is DNA methylation, which consists of the methyl group at carbon 5 of the cytosine. Methylation of cytosine residues in DNA provides a mechanism for a gene control expression.
DNA methylation in promotor region as well as coding sequences inhibits binding of regulatory protein and causes gene silencing [Frigola et al. 2005]. It has been estimated that up to 5% of cytosines are methylated in normal tissues and that this DNA methylation is necessary for controlling gene expression of tissue-specific housekeeping or imprinted genes and for maintaining genomic stability through silencing transposable elements of the genome. Genomic DNA can undergo changes not only in the sequence level but also by the addition or removal of chemical groups. Aberrant DNA methylation, appeared as either hyper-, or hypomethylation, is associated with changes in the phenotype of various diseases including brain tumours [Frigola et al. 2005].
The brain and other points of the nervous system are particularly vulnerable to the free radical damage for a number of reasons. The membrane lipids in brain contain high level of polyunsaturated fatty acid side chains, which are prone to free radical damage. Brain also takes up large quantities of oxygen contributing to the formation of reactive oxygen species. At the same time brain contains low level of antioxidant enzymes such as catalase, superoxide dismutase and glutathione peroxidase. Presence of iron, copper and manganese in the brain contribute significantly to the production of a highly reactive and very short living ROS via Fenton reaction [Kehrer 2000; Essick and Sam 2010]. Free radicals, and •OH in particular, cause damaging of DNA, proteins and lipids. They include for example 8-hydroxy-2-deoxyguanosine, 4-hydroxy-2-nonenal and others [Fraga et al. 2002; Tudek et al. 2010].
Gliomas are the most common primary tumours affecting the human central nervous system (CNS). They are classified in accordance with their histopatological features and clinical presentation. The most abundance gliomas are astrocytomas, oligodendrogliomas and oligoastrocytomas [Louis et al. 2007]. Astrocytomas occur with an incidence of 80-85% of all gliomas and glioblastoma multiforme (GBM) represent the most frequent malignant primary brain tumours. Various genes with frequent tumour related promoter hypermethylation have been identified in glioma [Martinez and Esteller 2010]. Gene regulation in tumours by promoter methylation has been established [Robertson 2005]. It has a prognostic and predictive potential in cancers. Therefore one can expect DNA methylation analysis to become an important diagnostic tool for many types of cancer.
Oxidative stress from aberrant accumulation of ROS over time can damage of proteins, lipids and nucleic acids and forms the molecular basis of free-radical background of cancer. It is well established that the oxidative stress is linked directly to cancer [Essick and Sam 2010; Grek and Tew 2010; Johnstone and Baylin 2010]. Although ROS modification to DNA has been broadly discussed in the past, its activity towards 5-methylcytosine, a main epigenetic marker, causing DNA demethylation has been overlooked for a long time [Berdasco and Esteller 2010].
Although DNA methylation has been recognized as a stable epigenetic mark, recently many data on loss of DNA methylation (DNA demethylation) has been collected. It can be that DNA demethylation is an active, enzymatic or chemical process of the methyl group removal through breaking a carbon-carbon bond. Genome-wide and gene-specific demethylation events are observed [Trewick et al. 2002; Martinez et al. 2009; Martinez and Esteller 2010]. The first occurs at specific times during early development, whereas the latter occurs in somatic cells responding to specific signals.
Many enzymes and various mechanisms have been proposed to carry out active DNA demethylation [Wu and Zhang 2010]. They include base m5C excision repair, deamination of m5C to T, nucleotide excision repair, oxidative demethylation and radical S-adenosylmethionine-based demethylation [Wu and Zhang 2010; Klug et al. 2010].
In addition to that, it is also possible for DNA to be demethylated randomly with very active hydroxyl radical [Kehrer 2000]. It is known that DNA molecule is subjected to a broad range of free radicals and oxidative injuries
The demethylation of m5C proceeds through 5-hydroxymethylcytosine intermediate [Guo et al. 2011]. The mechanism of this reaction is similar to that of radical SAM [Wu and Zhang 2010]. Imbalance of red-ox state in tumor cells affects the genomic methylation patterns what can be used to distinguish cancerous from normal brain cells, and to find correlations with their pathological features [Bart et al. 2005].
There are evidences which support the existence of DNA demethylation in vertebrate cells, although the mechanism of that process is not clear [Wu and Zhang 2010].
A low amount of m5C in human DNA and a limited availability of brain tumour tissues, prompted us to look for a new and suitable method of m5C determination with diagnostic potential. We have applied a nucleic acid postlabelling approach with [γ-32P]-ATP and T4 polynucleotide kinase (T4 PNK) to analyze DNA components with the thin layer two dimensional chromatography (TLC) and particularly for a quantitative assessment of the modified nucleotides (Fig. 2).
It seems that deamination and demethylation of m5C effected with hydroxyl radical oxidation, leads to thymine (T) and cytosine (C) formation, respectively (Fig. 1). These bases obtained from m5C are naturally occurring in DNA and therefore we included them in the equation: R= [m5C/ (m5C+C+T)] ×100, for m5C assessment. In this way R represents the amount of m5C in relation to all pyrimidines (basic bases) present in DNA. We assume R as global methylation coefficient.
Before we began the analysis of m5C in human brain tumours DNA, we have checked the effect of tissue samples handling on the assignment of m5C. Tumour tissues were resected and handled in three different conditions. For the same tissue sample, one part was freshly frozen (FF), immediately put on dry ice, the other was formalin-fixed, paraffin embedded (FFPE) and the third one was stored for 3 hrs at room temperature on the bench. For DNA isolation, the tissue from FFPE was recovered as described previously [Sanchez-Navarro et al. 2010]. DNA isolated from all differently treated tissue samples showed changes in global amount of m5C (Fig. 3).
It is known that the development of molecular tests for clinical use has been limited by the lack of good available clinical samples for validation of candidate biomarkers. FF samples are difficult to collect and store for large scale studies, but FFPE samples on the other hand are stable at room temperature and easily to store. However the last approach has some disadvantages. Recently, it has been shown that RNA isolated from FFPE is a poor material for gene expression analysis due to its deep degradation [Farragher et al. 2008; Sanchez-Navarro et al. 2010].
Formalin fixation and paraffin embedding is the most commonly used method worldwide for tissue storage. This method preserves the tissue integrity but causes extensive damage to nucleic acids within the tissue. There is a huge resource of FFPE tissues specimens held in histopathology departments around the world. The samples provide an invaluable resource for studying the molecular basis of disease, making it possible to perform large retrospective studies correlation molecular features with therapeutic response and clinical out come [Farragher et al. 2008]. We have clearly showed that DNA in FFPE samples is degraded (Fig. 3) and observed significant demethylation in cellular DNA is due to oxidative damage [Tudek et al. 2010]. The highest DNA methylation level we observed for DNA isolated from fresh frozen tissues. The majority of studies to date have used high quality RNA from FF samples, however those studies have been restricted due to the small number of samples [Farragher et al. 2008]. Significantly lower amount of m5C was observed for FFPE tissues and severe hypomethylation for DNA from the cells stored at room temperature. One can conclude that m5C demethylation is effected by cellular oxidative damage which is reduced by deep freezing of a tissue sample immediately after tumor resection. A cellular damage occurring during embedding in paraffin, which includes heating up step in liquid paraffin, significantly stimulates demethylation has been observed earlier [Barciszewska et al. 2006; Blow 2007]. One can conclude that the decrease of DNA m5C is a consequence of severe DNA oxidation including m5C with •OH.
The goal of our studies was to understand the biology of malignant gliomas on the level that leads to the development of new diagnostic method.
We have analyzed the global level m5C in DNA samples from 577 individuals with brain tumours aged 11 - 80. Histopatological analysis of brain tumours was done according to WHO 2007 rules [Louis at al. 2007]. There were 285 males (49.5%) and 292 (50.5%) females.
The biggest group included patients of 41-70 years old. The highest ratio of patients at the time of diagnosis showed a group aged 51-60 years. The median age of patients at the time of diagnosis was 53.4±13.2 years (Fig. 4).
To correlate human brain tumours malignancy established with pathomorphological analysis with global DNA methylation, we have analyzed the genomic m5C content in DNA from human brain tissues of different gliomas. (Fig. 5, Table 1).
Human tumours often display genome-wide DNA hypomethylation, which promotes cancer through the effect on chromosomal stability [Gaudet et al. 2003; Eden 2003; Yamada et al. 2005; Nishiyama et al. 2005].
One can see that m5C content in different human brain tumours varies very much (Fig. 5, Table 1). It is known that hydroxylation of m5C promotes active DNA demethylation in the adult brain [Guo et al. 2011]. Analysis patients’ groups with high grade glioma shows that m5C content (R) decrease as malignancy increases (Fig. 6). The most abundant are gliomas astrocytomas, oligodendrogliomas or tumours with morphological features of both astrocytes and oligodendrocytas called oligoastrocytomas (Table 1). The histological classification is followed by grading (from I to IV) which expresses the tumour malignancy with IV being the most malignant. Astrocytic tumours are subsequently graded with I (pilocytic astrocytoma), II e.g. diffuse astrocytoma, III (anaplastic astrocytoma) and IV (glioblastoma multiforme). Oligodendrogliomas and astrocytomas are graded furthermore as with grade II or III (anaplastic). The highest DNA demethylation is observed for glioblastoma multiforme (Fig. 6).
These results are in agreement with previous observations done for a smaller group of patients [Zukiel 2004]. Importantly these data are supported by others, showed that primary glioblastoma and established glioma cell lines show significant reduction of m5C content compared with normal brain tissue [Cadieux et al. 2006]. Furthermore one can see that grade III shows R in the range 1 - 1.2, but for WHO IV R coefficient is below 0.5 (Fig. 6). This is the lowest level of DNA methylation observed ever, not only for high grade gliomas. Because the correlation of m5C content (R) and WHO grade is linear (Fig. 6), therefore R can be used as a probe of tumorgenesis. One can clearly see that the global DNA methylation analysis easily differentiate low and high grade tumours as well as metastatic (Fig. 7). Different relations occur for meningeomas (Fig. 8, Table 2).
The DNA methylation in meningiomas is on very similar level. The R value is between 0.86 and 1.59. It means that red-ox processes in these tumour cells are not so intensive.
If so, one can ask whether genomic methylation level can be a good diagnostic marker for the early tumour detection in the clinical practice [Hatada et al. 2006]. We have found that the extent of DNA demethylation process is different and specific for various diseases (Fig. 9). The lowest level of DNA methylation is observed for very aggressive tumours like glioblastoma and anaplastic astrocytoma. On the other hand methylation of DNA in colorectal cancer or pilocytic astrocytoma is higher. One can also see different m5C content in DNA from blood of patients with other diseases. It means that the global methylation analysis can be used as diagnostic tool [Widschwendter and Jones 2002; Lavon et al. 2010]
This method of nucleic acid compounds analysis can be also used as a quality control test of DNA. Currently for DNA isolation from different tissues, various isolation kits are used. Usually such material is good for cloning and enzymatic analysis However for molecular characteristic DNA should be RNA free. A contamination with RNA can be easily established with our method.
Mechanisms of regulation of DNA methylation are an important question, which has elicited much attention over the past decade. Recently many ideas have been proposed for mechanism of DNA demethylation. In addition to that, we have proposed a genomic one effected with hydroxyl radical oxidative damage. It turned out that the global methylation level of DNA provides information on grade cancer and progress of a disease.
This work was supported with the research grant from Ministry of Science and Informatization (MNII) Nr N N401 066338 (to M.B.) and N N403 219637 (to S.N.)
Barciszewska-M A. Murawa D. Gawronska I. Murawa P. Barciszewska M. Z. 2007Analysis of 5-methylcytosine in DNA of breast and colon cancer tissues. IUBMB Life 59 1 6
Barciszewska-M A. Nowak S. Żukiel R. i. in 2006Wpływ przechowywania tkanki nowotworowej na zawartość 5metylocytozyny w DNA guzów mózgu. Neuroskop 8:160-162 (Poland)
Bart A. van Passel M. W. van Amsterdam K. van der Ende A. 2005Direct detection of methylation in genomic DNA. Nucleic Acids Res 33:e124
Berdasco M. Esteller M. 2010Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19 698 711
Blow N. 2007Tissue issues. Nature 448 959 962
Cadieux B. Ching T. T. Vaden Berg. S. R. et al. 2006Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66 8469 8476
Eden A. Gaudet F. Waghmare A. Jaenisch R. 2003Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455 EOF 455 EOF
EE Essick Sam. F. 2010Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer. Oxid Med Cell Longev 3 168 177
Farragher S. M. Tanney A. Kennedy R. D. Harkin D. P. 2008RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 130 435 445
Fraga M. F. Uriol E. Borja Diego. L. Berdasco M. Esteller M. MJ Cañal Rodríguez. R. 2002High-performance capillary electrophoretic method for the quantification of 5-methyl 2’-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 23 1677 1681
Frigola J. Sole X. Paz M. F. Moreno V. Esteller M. Capella G. MA Peinado 2005Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Human Molecular Genetics 14 319 326
Gaudet F. Hodgson J. G. Eden A. Jackson-Grusby L. Dausman J. Gray J. W. Leonhardt H. Jaenisch R. 2003Induction of tumors in mice by genomic hypomethylation. Science 300 489 492
Grek CL, Tew KD 2010Redox metabolism and malignancy. Curr Opin Pharmacol 10 362 368
Guo J. U. Su Y. Zhong Ch. Guo-li Ming. G. Song H. 2011Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145 1 12
Hatada I. Fukasawa M. Kimura M. Morita S. Yamada K. Yoshikawa T. Yamanaka S. Endo C. Sakurada A. Sato M. Kondo T. Horii A. Ushijima T. Sasaki H. 2006Genome-wide profiling of promoter methylation in human. Oncogene 25 3059 3064
Johnstone SE, Baylin SB 2010Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat Rev Genet 11 806 812
Jomova K. Valko M. 2011Advances in metal-induced oxidative stress and human disease. Toxicology 283 65 87
Kehrer JP 2000The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149 43 50
Klug M. Heinz S. Gebhard C. Schwarzfischer L. Krause S. W. Andreesen R. Rehli M. 2010Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels. Genome Biol 11: R63 EOF
Lavon I. Refael M. Zelikovitch B. Shalom E. Siegal T. 2010Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 12 173 180
Li M. Hu S. Shen Z. He X. Tao S. Dong L. Zhu Y. 2009High-performance capillary electrophoretic method for the quantification of global DNA methylation: Application to methotrexate-resistant cells. Anal Biochem 387 71 75
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P ( 2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109 114 97 109
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA 2001Malignant glioma: genetics and biology of a grave matter. Genes Dev 15 1311 1333
Martinez R. Esteller M. 2010The DNA methylome of glioblastoma multiforme. Neurobiol Dis 39 40 46
Martinez R. Martin-Subero J. I. Rohde V. Kirsch M. Alaminos M. Fernandez A. F. Ropero S. Schackert G. Esteller M. 2009A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4 255 264
Miller SA, Dykes DD, Polesky HF 1988A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215 EOF 1215 EOF
Nishiyama R. Qi L. Tsumagari K. Weissbecker K. Dubeau L. Champagne M. Sikka S. Nagai H. Ehrlich M. 2005A DNA repeat, NBL2, is hypermethylated in some cancers but hypomethylated in others. Cancer Biol Ther 4 440 448
Pelizzola M, Ecker JR ( 2010) The DNA methylome. FEBS Lett. 2010 Nov 5. [Epub ahead of print
Rao A. V. Balachandran B. 2002Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 5 291 309
Reale A. Matteis G. D. Galleazzi G. Zampieri M. Caiafa P. 2005Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene 24 13 19
Robertson KD 2005DNA methylation and human disease. Nat Rev Genet 6 597 610
Sánchez-Navarro I. Gámez-Pozo A. González-Barón M. Pinto-Marín A. Hardisson D. López R. Madero R. Cejas P. Mendiola M. Espinosa E. Vara J. A. 2010Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques 48 389 397
Sciumè G. Santoni A. Bernardini G. 2010Chemokines and glioma: invasion and more. J Neuroimmunol 224 8 12
Soh Y. Shin M. H. Lee J. S. Jang J. H. Kim O. H. Kang H. Surh Y. J. 2003Oxidative DNA damage and glioma cell death induced by tetrahydropapaveroline. Mutat Res 544 129 142
Trewick S. C. Henshaw T. F. Hausinger R. P. Lindahl T. Sedgwick B. 2002Oxidative demethylation by Escherichia coli AlkB directly reverts DNA base damage. Nature 419 174 178
Tudek B. Winczura A. Janik J. Siomek A. Foksinski M. Oliński R. 2010Involvement of oxidatively damaged DNA and repair in cancer development and aging. Am J Transl Res 2 254 284
Ulrey C. L. Liu L. Andrews L. G. Tollefsbol T. O. 2005The impact of metabolism on DNA methylation. Hum Mol Genet 14:R 139 147
Widschwendter M. Jones P. A. 2002DNA methylation and breast carcinogenesis. Oncogene 21 5462 5482
Widschwendter M. Jones P. A. 2002The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin Cancer Res 8 17 21
Wu S. C. Zhang Y. 2010Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 11 607 620
Yamada Y. Jackson-Grusby L. Linhart H. Meissner A. Eden A. Lin H. Jaenisch R. 2005Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 102 13580 13585
Zukiel R. Nowak S. Barciszewska-M A. Gawrońska I. Keith G. Barciszewska M. Z. 2004A simple epigenetic method for the diagnosis and classification of brain tumors. Mol Can Res 2 196 202